Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BLU-5937 IR · 1 trial · 2 indications
To assess the comparison between Cmax following administration of an Extended Release tablet formulation and an Immediate Release reference formulation.
To assess the comparison between Cmin following administration of an Extended Release tablet formulation and an Immediate Release reference formulation.
To assess the comparison between AUC following administration of an Extended Release tablet formulation and an Immediate Release reference formulation.
To assess the comparison between C24 following administration of an Extended Release tablet formulation and an Immediate Release reference formulation.
| Arm | Type | Description |
|---|---|---|
| Immediate Release formulation | ACTIVE_COMPARATOR | IR Formulation |
| Extended Release formulation | EXPERIMENTAL | ER formulation |
| Name | Type | Description |
|---|---|---|
| BLU-5937 IR | DRUG | Each subject will receive two single and multiple administrations of Immediate Release reference formulation |
| BLU-5937 ER | DRUG | Each subject will receive single and multiple oral administrations of Extended Release formulation |
Inclusion Criteria: * Healthy males or non-pregnant, non-lactating healthy females Exclusion Criteria: * History of clinically significant cardiovascular, renal, hepatic, metabolic, dermatological, respiratory, GI, neurological, endocrine, haematological, immunological or psychiatric disorder, as...
BLU-5937 IR is an investigational small molecule being developed for the treatment of cough. It is currently in Phase 1 clinical development. The drug is being studied in healthy volunteers to assess its pharmacokinetics, which is how the body absorbs, distributes, metabolizes, and excretes the drug.
BLU-5937 IR is being developed by GSK plc, a global biopharmaceutical company. GSK is listed on the stock exchange under the ticker symbol GSK. The drug is in Phase 1 clinical development for the treatment of cough.
BLU-5937 IR is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 clinical trial has been completed to evaluate the drug's pharmacokinetics in healthy volunteers.
BLU-5937 IR has one completed Phase 1 clinical trial, identified as NCT05570539. The trial, titled 'Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation,' enrolled 30 participants in the United Kingdom. The study was active-controlled and included healthy volunteers aged 18 years and older.
BLU-5937 IR is the immediate release formulation of the drug BLU-5937. The clinical trial NCT05570539 compared BLU-5937 extended release prototypes against the BLU-5937 immediate release reference formulation, indicating that BLU-5937 IR is a specific version of the drug with immediate release characteristics.